Amgen bispecific antibody therapy phase III Linchuan results announced reduce the risk of disease
Amgen today announced that the results of a phase III clinical trial of the bispecific antibody therapy Blincyto (blinatumomab) for the first relapse of high-risk B-cell precursor acute lymphoblastic leukemia in children with acute lymphoblastic leukemia was published in (JAMA). Compared with consolidation chemotherapy, Blincyto can significantly prolong the event-free survival of patients (events include recurrence, death, new tumors or failure to achieve complete remission). Blincyto is a bispecific T cell adaptor (BiTE) developed by Amgen. One end binds to the CD19 antigen expressed on the surface of B cells, and the other end recruits T cells to the vicinity of cancer cells to promote their killing of cancer cells. Blincyto has been approved by the FDA to treat patients with relapsed/refractory B-cell ALL. It has also received accelerated approval from the FDA. The treatment has entered the first or second complete remission, but minimal residual disease (MRD) is greater than 0.1% of B-cell ALL. patient.
3-Fluoro-2-formylpyridine, CAS: 31224-43-8
(1R)-5-Bromo-1-methyl-2-trityl-2,3-dihydro-1H-isoindole, CAS: 194805-14-6
4-Bromo-2,5-difluoroanisole, CAS: 202865-60-9
2-Chloro-4'-fluoroacetophenone, CAS: 456-04-2
3-Bromo-2-fluoropyridine, CAS: 36178-05-9